Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)

Legend Biotech Corporation, a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced patient-reported outcome data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology Annual Meeting.